EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real‐world data study

Diego Santos-García iD, Lydia López-Manzanares, Inés Muro iD, Pablo Lorenzo-Barreto iD, Elena Casas Peña, Rocío García-Ramos, Tamara Fernández Valle, Carlos Morata-Martínez, Raquel Baviera-Muñoz, Irene Martínez-Torres, María Álvarez-Sauco, Déborah Alonso-Modino und 20 weitere

European Journal of Neurology · 2025-01 · 32 (1)

DOI: 10.1111/ene.16535 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 28.10.2024. Verfasst von Diego Santos-García und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario de A Coruña, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Carbidopa, Antiparkinson Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion is a recently developed device‐aided therapy for advanced Parkinson disease (PD) patients. The aim of this study was to report real‐world evidence about the effectiveness, tolerability, and safety of LECIG in PD patients.

Methods

A multicenter observational retrospective study of the first patients who initiated LECIG in Spain was performed. All neurologists with an experience of at least two patients treated until 30 March 2024 were invited to participate. Data about effectiveness and safety from the medical records (V0, pre‐LECIG; V1, initiation of LECIG; V2, post‐LECIG follow‐up) with a total of 246 variables were collected.

Results

Seventy‐three PD patients (61.6% males, 70.1 ± 9.1 years old) from 21 Spanish centers with a mean disease duration of 14.4 ± 6.3 years (range = 5–31) were included. Twenty‐six patients (35.6%) were switched directly from levodopa–carbidopa intestinal gel. The mean exposure to LECIG was 177.3 ± 110.5 days (range = 7–476). The mean daily OFF time decreased from 5.2 ± 3 (pre‐LECIG) to 1.9 ± 1.8 (post‐LECIG; n = 66, p < 0.0001). Global improvement was observed in >85% of the patients. No significant change was detected in the levodopa equivalent daily dose from V0 to V2. Only 7% received 24‐h infusion, and 24.7% required more than one cartridge per day at V2. Thirty‐four patients (46.6%) had at least one adverse event related to LECIG and/or the device system. Five patients (6.8%) discontinued LECIG.

Conclusions

LECIG was safe and effective in advanced PD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaCarbidopaAntiparkinson AgentsCatecholsDrug CombinationsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesNitrilesTreatment OutcomeSpainGelsAged, 80 and over

Stichwörter der Autor:innen

Parkinson diseaseeffectivenessinfusionlevodopa–entacapone–carbidopasafety

Substanzen

LevodopaCarbidopaAntiparkinson AgentsCatecholsDrug Combinationsentacaponecarbidopa, levodopa drug combinationNitrilesGels

Autor:innen und Institutionen

  • Department of Neurology, Hospital Universitario de A Coruña, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Grupo de Investigación en Enfermedad de Parkinson y otros Trastornos del Movimiento, Instituto de Investigación Biomédica de A Coruña, A Coruña, Spain.
  • Hospital San Rafael, A Coruña Fundación Degen, A Coruña, Spain.
  • Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Hospital Universitario la Princesa, Madrid, Spain.
  • Hospital Clínico Universitario San Carlos, Madrid, Spain.

ORCID-Profile: Diego Santos-García, Inés Muro, Pablo Lorenzo-Barreto, Juan Carlos Martínez-Castrillo, Ana Belén Perona, Esther Cubo, Mar Carmona, Pedro García Ruíz

Zitieren

APA

Santos-García, D., López-Manzanares, L., Muro, I., Lorenzo-Barreto, P., Casas Peña, E., García-Ramos, R., Fernández Valle, T., Morata-Martínez, C., Baviera-Muñoz, R., Martínez-Torres, I., Álvarez-Sauco, M., Alonso-Modino, D., Legarda, I., Valero-García, M. F., Suárez-Muñoz, J. A., Martínez-Castrillo, J. C., Perona, A. B., Salom, J. M., Cubo, E., …, & Mata, M. (2025). Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real‐world data study. European Journal of Neurology, 32(1). https://doi.org/10.1111/ene.16535

Vancouver

Santos-García D, López-Manzanares L, Muro I, Lorenzo-Barreto P, Casas Peña E, García-Ramos R, et al. Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real‐world data study. European Journal of Neurology. 2025;32(1). doi:10.1111/ene.16535

BibTeX
@article{SantosGarca2025,
  author = {Santos-García, Diego and López-Manzanares, Lydia and Muro, Inés and Lorenzo-Barreto, Pablo and Casas Peña, Elena and García-Ramos, Rocío and Fernández Valle, Tamara and Morata-Martínez, Carlos and Baviera-Muñoz, Raquel and Martínez-Torres, Irene and Álvarez-Sauco, María and Alonso-Modino, Déborah and Legarda, Inés and Valero-García, María Fuensanta and Suárez-Muñoz, José Andrés and Martínez-Castrillo, Juan Carlos and Perona, Ana Belén and Salom, Jose María and Cubo, Esther and Valero-Merino, Caridad and López-Ariztegui, Nuria and Sánchez Alonso, Pilar and Novo Ponte, Sabela and Gamo González, Elisa and Martín García, Raquel and Espinosa, Raúl and Carmona, Mar and Feliz, Cici Esmerali and García Ruíz, Pedro and Muñoz Ruíz, Teresa and Fernández Rodríguez, Beatriz and Mata, Marina},
  title = {Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real‐world data study},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {1},
  doi = {10.1111/ene.16535}
}
Kostenlos starten →